Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Understanding the behavior of tiny droplets in our cells could aid the search for new treatments. A team of Leiden ...
The Cool Down on MSN11h
Supermarket to roll out major change at 77 locations nationwide: 'We're excited for our customers'"The initiative reflects our continuous efforts." Supermarket to roll out major change at 77 locations nationwide: 'We're ...
The Anderson transition is a phase transition that occurs in disordered systems, which entails a shift from a diffusive state ...
The Food and Drug Administration (FDA) has expanded the labeling for Izervayâ„¢ (avacincaptad pegol intravitreal solution) to include longer-term ...
Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...
Research and development expenses were $12.6 million for the second quarter of fiscal 2025, compared with $12.0 million for the same period a year ago, with the increase primarily attributable to ...
Acoramidis is the first and only approved ATTR-CM treatment in the U.S. and EU with a label specifying near-complete stabilization (≥90%) Relative increases in serum TTR concentrations resulting from ...
XCOM-like strategy game Xenonauts 2 just got a strong update with new combat mechanics and more, creating an excellent ...
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback